SARS CoV-2 vaccine AND rituximab. Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response" by Verhoeven Joint Bone Spine. 2021;88:105258.
作者信息
Mungmunpuntipantip Rujittika, Wiwanitkit Viroj
机构信息
Private Academic Consultant, Bangkok, Thailand.
Honorary professor, Dr DY Patil University, Pune, India.
出版信息
Joint Bone Spine. 2022 Jan;89(1):105281. doi: 10.1016/j.jbspin.2021.105281. Epub 2021 Sep 29.
Abstract
摘要
相似文献
1
SARS CoV-2 vaccine AND rituximab. Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response" by Verhoeven Joint Bone Spine. 2021;88:105258.严重急性呼吸综合征冠状病毒2疫苗与利妥昔单抗。评论：Verhoeven等人在《关节与脊柱》杂志上发表的“严重急性呼吸综合征冠状病毒2疫苗与利妥昔单抗，时机可能是获得更好疫苗反应的关键”。2021年；88:105258 。
Joint Bone Spine. 2022 Jan;89(1):105281. doi: 10.1016/j.jbspin.2021.105281. Epub 2021 Sep 29.
2
Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response" by Verhoeven et al. Joint Bone Spine 2021;88:105258.对Verhoeven等人所著《SARS-CoV-2疫苗与利妥昔单抗，时机可能是获得更好疫苗反应的关键》的评论。《关节与脊柱》2021年；88:105258 。
Joint Bone Spine. 2022 Oct;89(5):105408. doi: 10.1016/j.jbspin.2022.105408. Epub 2022 May 13.
3
SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response.严重急性呼吸综合征冠状病毒2型疫苗与利妥昔单抗，接种时机可能是获得更好疫苗反应的关键。
Joint Bone Spine. 2021 Dec;88(6):105258. doi: 10.1016/j.jbspin.2021.105258. Epub 2021 Sep 2.
4
Answer to Mungmunpuntipantip et al. "SARS CoV-2 vaccine AND rituximab" Joint Bone Spine 2021;88:105281.对蒙蒙蓬蒂潘蒂普等人《严重急性呼吸综合征冠状病毒2疫苗与利妥昔单抗》的回复，《关节与脊柱》2021年；88:105281
Joint Bone Spine. 2022 Jan;89(1):105283. doi: 10.1016/j.jbspin.2021.105283. Epub 2021 Oct 1.
5
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.CEPI/BC 2020 年 3 月 12-13 日会议共识总结报告：评估 COVID-19 疫苗引起疾病增强的风险。
Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25.
6
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.利妥昔单抗治疗患者的新型冠状病毒2型疫苗接种：体液免疫受损但细胞免疫反应可诱导的证据
Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.
7
SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger? Comment on: "Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?" by Manzo et al. Joint Bone Spine 2021;88:105150.严重急性呼吸综合征冠状病毒2、风湿性多肌痛和巨细胞动脉炎：新冠疫苗接种会成为诱因吗？对曼佐等人所著《严重急性呼吸综合征冠状病毒2会引发风湿性多肌痛复发吗？》的评论。《关节与脊柱》2021年；88:105150
Joint Bone Spine. 2022 Jan;89(1):105282. doi: 10.1016/j.jbspin.2021.105282. Epub 2021 Sep 29.
8
Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.关于“利妥昔单抗治疗患者的新型冠状病毒2疫苗接种：体液免疫受损但细胞免疫可诱导的证据”的通信
Ann Rheum Dis. 2021 Oct;80(10):e162. doi: 10.1136/annrheumdis-2021-220756. Epub 2021 Jul 16.
9
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.利妥昔单抗而非其他抗风湿疗法，与风湿性疾病患者对SARS-CoV-2疫苗的血清学反应受损有关。
Ann Rheum Dis. 2021 Oct;80(10):1357-1359. doi: 10.1136/annrheumdis-2021-220604. Epub 2021 May 11.
10
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
Zotero 插件